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Myelin-Associated Glycoprotein (MAG), a major inhibitor of axonal growth, is a member
of the immunoglobulin (Ig) super-family. Importantly, MAG (also known as Siglec-4)
is a member of the Siglec family of proteins (sialic acid-binding, immunoglobulin-like
lectins), MAG binds to complex gangliosides, specifically GD1a and/or GT1b. Therefore,
it has been proposed as neuronal receptors for MAG inhibitory effect of axonal growth.
Previously, we showed that MAG binds sialic acid through domain 1 at Arg118 and is
able to inhibit axonal growth through domain 5. We developed a neurite outgrowth (NOG)
assay, in which both wild type MAG and mutated MAG (MAG Arg118) are expressed on
cells. In addition we also developed a soluble form NOG in which we utilized soluble
MAG-Fc and mutated MAG (Arg118-Fc). Only MAG-Fc is able to inhibit NOG, but not
mutated MAG (Arg118)-Fc that has been mutated at its sialic acid binding site. However,
both forms of membrane bound MAG- and MAG (Arg118)- expressing cells still inhibit
NOG. Here, we review various results from different groups regarding MAG’s inhibition of
axonal growth. Also, we propose a model in which the sialic acid binding is not necessary
for the inhibition induced by the membrane form of MAG, but it is necessary for the
soluble form of MAG. This finding highlights the importance of understanding the different
mechanisms by which MAG inhibits NOG in both the soluble fragmented form and the
membrane-bound form in myelin debris following CNS damage.
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INTRODUCTION
Myelin-associated glycoprotein (MAG), a member of the immunoglobulin (Ig) super-
family, contains five Ig-like domains in its extracellular sequences, a single transmembrane
domain, and a short cytoplasmic domain (Figure 1A; Lai et al., 1987a,b; Salzer et al., 1987,
1990). Since its recognition as a potent inhibitor of central nervous system (CNS) axon
regeneration (McKerracher et al., 1994; Mukhopadhyay et al., 1994), enormous efforts have
been directed at identifying its receptors. MAG was first reported as a sialic acid binding
protein that interacts with the complex gangliosides GT1b and GD1a (Vinson et al., 2001).
The search for receptors that transduce its inhibitory effect resulted in the discovery of
NgR1, NgR2, and PirB as functional MAG receptors (Domeniconi et al., 2002; Liu et al.,
2002; Venkatesh et al., 2005; Atwal et al., 2008). MAG was also shown to bind and signal
through β-1 integrin (Goh et al., 2008). Recently, the inhibition of neurite outgrowth
(NOG) of cortical neurons plated on MAG-expressing Chinese hamster ovary (MAG-CHO)
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FIGURE 1 | Structural features of myelin-associated glycoprotein (MAG). (A) Structural features of MAG. Arginine 118, the sialic acid binding site and also
part of the RGD site, is located within domain 1. The inhibition site is located within domain 5. (B) In soluble MAG-Fc, the protein portion after domain 5 is replaced
by the Fc domain.
cells was found to be independent of NgRs and gangliosides.
Rather, PTEN, a lipid phosphatase that activates AKT, was found
to mediate the MAG inhibitory signal, suggesting the existence of
other, as yet unknown, receptors (Perdigoto et al., 2011).
Discovering MAG receptors is critical for identifying
therapeutic targets for promoting axonal regeneration, and
it is also important to clarify the role of gangliosides in
MAG-induced inhibition of NOG. Here, we focus on the
relationship between MAG and sialic acid in gangliosides, please
see a recent extensive review of sialic acids (Schnaar et al.,
2014).
MAG AS A MEMBER OF THE SIGLEC
PROTEIN FAMILY
The Siglec protein family is a subgroup of the Ig super-family
that has similar amino acid sequences in the first four Ig-like
domains and shows sialic acid-dependent binding to cells (Kelm
et al., 1998). Members include sialoadhesin (Siglec-1), CD22
(Siglec-2), CD33 (Siglec-3), and MAG (Siglec-4; DeBellard et al.,
1996; Tang et al., 1997a; Kelm et al., 1998). Each member of the
Siglec family binds with different specificity. MAG preferentially
binds α2,3-linked sialic acid residues attached to O-linked
glycoconjugates (Kelm et al., 1994), CD22 binds to α2,6-linked
sialic acid attached to N-linked glycoconjugates, and sialoadhesin
and CD33 recognize α2,3-linked sialic acid attached to O- or
N-linked glycoconjugates (Kelm et al., 1994; Cornish et al.,
1998).
MAG is expressed early in development (for a thorough
description of MAG in normal tissue, see Baldwin and Giger,
2015) exclusively at the interface between myelinated axons
and periaxonal myelin membrane (Trapp et al., 1989).
MAG plays a role in axon-glial interactions (Schachner
and Bartsch, 2000) and influences myelin formation.
Genetic depletion of MAG results in altered myelination,
reduced axon caliber, reduced neurofilament spacing and
phosphorylation, and progressive axonal degeneration (Li et al.,
1994; Montag et al., 1994; Fruttiger et al., 1995; Yin et al.,
1998).
Early postnatal MAG-deficient mice exhibit delays in
the formation of compact myelin in the optic nerves and
reduced density of retinal ganglion cell axons surrounded
by compact myelin (Montag et al., 1994). Although
the ultrastructure of compact myelin is unaffected,
MAG-deficient mice exhibit a dilated periaxonal space and
abnormal formation of the periaxonal cytoplasmic collar
(Li et al., 1994; Montag et al., 1994). Some axons in MAG-
deficient mice are surrounded by more than one myelin sheath
(Bartsch, 1996). Moreover, in adult MAG-deficient mice,
oligodendrocytes show degeneration of distal processes in
the periaxonal space or within compact myelin, which is also
observed in immune-mediated demyelinating diseases including
multiple sclerosis (Rodriguez-Peña et al., 1993; Lassmann et al.,
1997). Thus, in the CNS, MAG is involved in the initiation
of myelination, formation of myelin sheaths, and long-term
maintenance of oligodendrocyte structure and myelin integrity.
In the peripheral nervous system (PNS), MAG seems to be
involved only in the formation of intact myelin and long-term
maintenance of myelin structure but not in the initiation of
myelination.
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Collectively, therefore, in vitro experiments and studies using
MAG-deficient mice show that MAG is a cell adhesion molecule,
a receptor that transduces signals into the interior of myelin-
forming glial cells, and a contributor to cross-talk between
myelin-forming glial cells and axons.
INHIBITORY SITE ON MAG
Using several chimeric constructs in which domains 4 and 5
of MAG are exchanged with the corresponding domains of
sialoadhesin, the Filbin lab showed that the MAG inhibition
site is on domain Ig-5 (Figure 1) and is distinct from the sialic
acid binding site on domain Ig-1 (Cao et al., 2007). Importantly,
several chimeric molecules containing the sialic acid binding site
sialoadhesin do not inhibit NOG, reinforcing the notion that
the sialic acid binding domain is not necessary for neuronal
inhibition (Cao et al., 2007). Another group arrived at a similar
conclusion using a different set of molecular tools focusing on
domain Ig-4 of neural cell adhesion molecule (N-CAM) and
domain Ig-5 of MOG (Wörter et al., 2009).
SIALIC ACID AS COMPONENT OF
GANGLIOSIDES
Gangliosides are glycosphingolipids containing one or more
sialic acid residues in their oligosaccharide structure (Sonnino
et al., 2007). They are components of all animal cell membranes
and are particularly abundant in the plasma membranes
of neurons. Gangliosides are complex lipids with a strong,
amphiphilic, big saccharide head-group and a double-tailed
hydrophobic moiety. The lipid moiety of gangliosides, shared
across sphingolipids, is called a ceramide and is constituted by a
long-chain amino alcohol termed sphingosine (Karlsson, 1970),
connected to fatty acids by an amide linkage. Sialic acid is a sugar
that differentiates gangliosides from neutral glycosphingolipids
and sulfatides and defines all derivatives of 5-amino-3,5-
dideoxy-d-glycero-d-galacto-non-2-ulopyranosonic acid or
neuraminic acid (Schauer, 1982). Gangliosides are positioned
to interact with other molecules in their own membrane and
molecules on opposing cell membranes (Lopez and Schnaar,
2009). Gangliosides are typically anchored in the outer leaflet
of the plasma membrane, where they are driven by ceramide
to partition laterally into lipid rafts, which are membrane
micro-domains containing other sphingolipids, cholesterol,
and signaling molecules. This lateral interaction in the
membrane normally results in ganglioside-mediated regulation
of membrane proteins, such as receptor kinases. Ganglioside
glycans also extend outward from the cell surface, where their
sialoglycans participate in intermolecular interactions. This
interaction with proteins on opposing membranes results in
ganglioside-mediated cell-cell recognition, such as myelin-axon
interaction.
Ceramide is the common precursor of glycosphingolipids
and sphingomyelin and is transported from the endoplasmic
reticulum to the Golgi apparatus by unknown mechanisms.
Glycosphingolipids are synthesized by the stepwise addition
of monosaccharide sugars to ceramide and the growing
FIGURE 2 | Partial biosynthesis pathway for major brain gangliosides.
Schematic biosynthetic relationship between major brain gangliosides and
their precursors. Disruption of the B4galnt1 gene blocks the synthesis of
gangliosides, including GT1b and GD1a, to which MAG binds. B4galnt1-
deficient mice lack all complex gangliosides but express higher levels of simple
gangliosides GM3 and GD3. Modified from Sheikh et al. (1999), reproduced
with permission.
sugar. Subsequent addition of galactose, sialic acid, and
N-acetylgalactosamine from their nucleotide sugar donors to
the growing saccharide chain generates penta, hexa, and
hepta saccharide glycans (Kolter et al., 2002). The ganglioside
biosynthetic pathway (Figure 2) involves a sequential process
of glycosylation via two main pathways: the ‘‘a’’ series (GM2,
GM1a, GD1a) and ‘‘b’’ series (GD2, GD1b, GT1b; van Echten
and Sandhoff, 1993). Each ganglioside is structurally more
complex than its precursor molecule, and the stepwise addition
of monosaccharide or sialic acid residues by specific membrane-
bound glycosyltransferases in the Golgi apparatus is catalyzed
by the same glycosyltransferases in both pathways. In an
investigation of the differential distribution of GM1, GD1a,
GD1b, and GT1b in the adult mouse CNS (Vajn et al., 2013),
GD1b and GT1b was expressed in gray and white matter, GM1
was expressed in white matter, and GD1a was expressed in
specific nuclei/tracts. This differential expression of gangliosides
could explain why MAG appears to use different receptors on
different neurons to inhibit NOG (Mehta et al., 2007; Venkatesh
et al., 2007).
B4GALNT1-DEFICIENT MICE
Among many glycosyltransferases, β1, 4 GalNAc-transferase (β1,
4 GalNAc-T; GM2/GD2 synthase; EC2.4.1.92), coded by the
gene B4GALNT1, plays an important role in the biosynthesis
of almost all complex gangliosides (Figure 2). Two different
groups independently disrupted the B4GALNT1 gene to generate
B4galnt1-deficient mice. Takamiya et al. (1996) disrupted exon
4 of the B4GALNT1 gene by inserting a neomycin-resistant
plasmid and found that B4galnt1-deficient mice express no
complex gangliosides but higher concentrations of the simple
gangliosides GD3 and GM3. By 12 weeks of age, B4galnt1-
deficient mice show decreased central conduction velocity but
normal brain weight and shape, myelination of white matter,
and myelinated fiber and synapse structure, suggesting that
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complex gangliosides are required for neuronal function but not
brain organogenesis. This lack of complex gangliosides might be
compensated by higher levels of GM3 and GD3 in these mice.
A later study reports that deficits exhibited by these B4galnt1-
deficient mice can be rescued by tissue-specific GalNacT
constructs. Using the neurofilament light promoter (restricted
to neurons) and proteolipid protein promoter (restricted to
myelinating glia, including oligodendrocytes and Schwann cells),
the restoration of complex gangliosides in neurons but not glia
was found to be critical for maintaining CNS integrity (Yao et al.,
2014).
Sheikh et al. (1999) generated a different strain of B4galnt1-
deficient mice using a vector, in which exon 6 and 7 and part of
exon 8 are deleted and replaced with a MC1NeoPolyA selection
cassette (Sheikh et al., 1999). These mice have a normal life span
but show decreased central myelination, central and peripheral
axonal degeneration, and increased levels of GD3 and GM3.
Similar to MAG-deficient mice, B4galnt1-deficient mice show
abnormalities, such as doubly myelinated axons with cytoplasm
between the two myelin sheaths. Whereas young B4galnt1-
deficient mice express normal levels of MAG, adult B4galnt1-
deficient mice show a ∼30% decline in MAG levels in the CNS
and PNS and develop Wallerian degeneration (Sheikh et al.,
1999). Sheikh et al. (1999) attribute the differences between
their findings and the findings of Takamiya et al. (1996) to
the fact that the first group’s animals were examined at a
young age, whereas the effects of B4galnt1 deficiency become
more prominent with increasing age. They argue that because
conduction velocity depends on myelination and axon diameter,
the decreased conduction velocity observed by the first group
could be attributed to myelination defects and axonal atrophy.
Indeed, in a later study, MAG protein but not mRNA was
found to decrease substantially by 12 months of age (Sun et al.,
2004).
The more recently generated double-heterozygous mice
carry null mutations in B4GALNT1 (called Galgt1) and
ST3GAL5 (called Siat9, which encodes GM3 synthase [CMP-
NeuAc:lactosylceramide α-2,3-sialytransferase; EC 2.4.99.9];
Yamashita et al., 2005). Although the mice are viable, they
exhibit neurodegeneration with severe pathology in white matter
and CNS axons. In addition, the mice were generated with
mutated ST3GAL2 and ST3GAL3, which are sialyltrasferase
genes responsible for terminal sialylation of gangliosides and
biosynthesis of GD1a and GT1b (Figure 2). These mice
exhibit dysmyelination marked by substantial reductions in
major proteins, myelinated axons, myelin thickness, and MAG
expression, as well as molecular defects in the Nodes of Ranvier
(Yoo et al., 2015), indicating that terminal sialylation is required
for optimal brain structure and function.
ROLE OF GANGLIOSIDES IN
MAG-MEDIATED INHIBITION OF NOG
In the NOG assay developed by the Filbin lab, primary neurons
are grown on a monolayer of control CHO or MAG-CHO
cells, and the growth of neurites is quantified 24 h later
(Mukhopadhyay et al., 1994). In this assay, MAG inhibits
the growth of postnatal neurons (Mukhopadhyay et al., 1994;
DeBellard et al., 1996). Also, removal of neuronal sialic acid
residues by sialidase treatment does not alter the inhibitory effect
of MAG on NOG (Tang et al., 1997a). The sialic acid binding site
on MAG was mapped at Arginine (Arg) 118, a highly conserved
residue in many Siglecs, which is part of a RGD site that binds and
signals through β-1 integrin (Goh et al., 2008). Arg 118 is located
in the first Ig-like domain. Surprisingly, mutations of this amino
acid to either Alanine or Aspartate do not affect the inhibitory
effect of MAG (Tang et al., 1997a), indicating that MAG-sialic
acid interactions might not be required for MAG inhibition.
The Filbin lab also used purified soluble forms of the
extracellular domain of MAG fused to the Fc portion (MAG-Fc;
Figure 1B) of human IgG1 (Kelm et al., 1994; Tang et al., 1997b).
In this modified, soluble-NOG assay, neurons are incubated
with MAG-Fc and then plated on L1-Fc substrate in wells
coated with anti-Fc antibodies. Although MAG-Fc inhibits the
outgrowth of neurites, no inhibition occurs when mutated Fc
constructs (MAG (R118A)-Fc or MAG (R118D)-Fc) are used
(Tang et al., 1997a), suggesting that MAG-sialic acid interactions
are necessary only when MAG is in soluble form. In addition,
a truncated form of MAG containing the first three Ig-like
MAG domains (MAG d1–3-Fc), which binds neurons in a sialic
acid-dependent manner, does not inhibit neurite growth in the
soluble-NOG assay (Tang et al., 1997a).
Similarly, Vinson et al. (2001) report that mutation of the
R118 residue in the first Ig-like domain reduces the potency of
MAG inhibition in the soluble-NOG assay. MAG specifically
binds both GT1b and GD1a, which are expressed at the surface
of MAG-responsive neurons. Pre-incubation of hippocampal
neurons (HNs) with increasing concentrations of alpha methyl
sialic acid 3 sialyllactose before addition of MAG-Fc blocks
MAG-Fc inhibition of NOG. Also, pre-incubation of HNs with
purified GT1b and GD1a blocks MAG- and MAG (R118A)-
Fc inhibition, indicating that MAG-GT1b interactions on the
cell surface may be a mechanism of MAG-induced inhibition of
NOG (Vinson et al., 2001).
Vyas et al. (2002) report that GD1a and GT1b are functional
nerve cell ligands for MAG. Treatment of cerebellar granular
neurons (CGNs) with V. cholerae neuraminidase, which removes
sialic acid from cell surfaces, reverses MAG inhibition. Under
the same conditions, depletion of gangliosides using the
glycosylceramide synthase inhibitor P4 reverses MAG inhibition
of NOG. Also, CGNs from mice lacking the complex gangliosides
GD1a and GT1b (i.e., B4galnt1-deficient mice) are less vulnerable
to MAG inhibition. Furthermore, experiments where CGNs
are incubated on detergent-extracted myelin or membrane
purified from MAG-CHO cells provide additional evidence of
the importance of complex gangliosides when MAG is expressed
in soluble form.
The Filbin lab also showed that soluble MAG released from
damaged white matter, consisting of a proteolytic MAG fragment
containing the entire extracellular domain (d1–5), inhibits axonal
regeneration (Tang et al., 2001). This finding highlights the
importance of understanding the different mechanisms by which
MAG inhibits NOG in both the soluble fragmented form and the
membrane-bound form in myelin debris following CNS damage.
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 April 2016 | Volume 9 | Article 21
Al-Bashir et al. Myelin-Associated Glycoprotein (MAG) Sialic Acid Interactions
FIGURE 3 | The sialic acid binding on MAG R118 is critical for inhibition of axonal regeneration by soluble MAG-Fc but not by MAG expressed by
Chinese hamster ovary (CHO) cells. Inhibition of NOG by MAG-CHO (A), mutated MAG (R118A)-CHO (B) and soluble MAG-Fc (C). However, mutated soluble
MAG (R118A)-Fc does not inhibit NOG (D) nor, a truncated form of soluble MAG (d1–3)-Fc, that binds to sialic acid but lacks the inhibitory domain of MAG (E).
An interesting experiment by Vinson et al. (2001) sheds
light on the function of sialic acid. They demonstrated that
aggregating sialic acid, achieved by adding IgM generated from
anti-GT1b antibodies, reduces NOG in dose-dependent manner
(Vinson et al., 2001), mimicking the inhibitory effect of MAG.
Also, pre-incubation of GT1b antibody with purified GT1b,
but not with other purified gangliosides, blocks inhibition of
NOG by anti-GT1b antibodies. Finally, a Rho kinase inhibitor
blocks inhibition of NOG by MAG or anti-GT1b antibody
in both HNs and CGNs (Vinson et al., 2001). By contrast,
Vyas and colleagues show that highly multivalent clustering of
either anti-GT1b or anti-GD1a, achieved using IgG1 monoclonal
antibody pre-incubated with secondary anti-Fc, mimics MAG-
mediated inhibition of NOG (Vinson et al., 2001; Vyas et al.,
2002). This inhibition cannot be due to gangliosides, which
do not have transmembrane properties, but rather to another
molecule that crosses the membrane and perhaps interacts with
gangliosides.
Indeed, lipid rafts have been suggested as a possible
transducer of MAG inhibitory signals (McKerracher, 2002). One
study in particular indicates that myelin rafts may associate with
neurons (Vinson et al., 2003). Specifically, MAG is found in a
section of the membrane characterized by its solubility to Triton
X-100 but not to Lubrol WX. MAG-Fc detected this section
in lipid raft preparations from CGNs in a region containing
GT1b, p75, Rho, NgR, and caveolin (Vinson et al., 2003). In
another study, MAG-Fc, anti-GD1a, or anti-GT1b brings p75
(and also Flotilin-1, a marker of lipid rafts) to the Brij-58
insoluble lipid raft fraction isolated from mouse CGNs (Fujitani
et al., 2005). Also, biochemical studies show the binding of
GT1b and GM1 to NgR1 (Williams et al., 2008). Analytical
ultracentrifugation analysis shows that GT1b and GM1, but
not asialo-GM1, induce additional peaks in a concentration-
dependent manner, with higher sedimentation coefficients than
the coefficient of NgR1(310)-Fc. When the GT1b binding site
on NgR1 is blocked with a cyclic peptide, GT1b antibody fails
to inhibit NOG. Finally, GT1b antibody does not inhibit NOG
in neurons from NgR1 knock-out mice (Williams et al., 2008).
Together, these findings indicate that the effect of GT1b antibody
requires NgR1.
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CONCLUSIONS: A WORKING MODEL
In summary, MAG binds sialic acid at Arg118, which is located
in domain 1 of MAG, distant from the inhibitory site in domain
5. Soluble MAG requires sialic acid binding for inhibition of
NOG. When Arg118 is mutated, inhibition by soluble MAG
is abolished. However, sialic acid binding is not required for
MAG-expressing CHO cells to inhibit NOG. We conclude that
there are at least two binding sites on MAG—the sialic acid
binding site at Arg 118 and inhibitory site at domain 5. Therefore,
we propose a two-site model for MAG inhibition (Figure 3).
When CHO cells express MAG, both sites engage neurons,
and NOG is inhibited (Figure 3A). When CHO cells express
MAG that is mutated at its sialic acid binding site, NOG is still
inhibited (Figure 3B). However, it is unclear whether another
molecule helps achieve the correct orientation for inhibition
to occur and/or allow membrane-associated MAG to achieve
the correct conformation to interact with the receptor. When
soluble MAG is added to neurons, both sites engage neurons,
and NOG is inhibited (Figure 3C). By contrast, when soluble
MAG is mutated at the sialic acid binding site, it cannot bind to
neurons, and the inhibition site cannot be engaged, resulting in
no inhibition of NOG (Figure 3D). When soluble MAG (d1–3)
is added to neurons, it binds through its sialic acid binding site
but does not inhibit axonal growth because the inhibition site
is absent (Figure 3E). This model suggests that gangliosides are
necessary in order to inhibit NOG, but only when soluble form
of MAG is present; perhaps gangliosides help achieve correct
alignment to NgR, but not when MAG is expressed by CHO cells.
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